228410-90-0

Basic information

• Product Name: 5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE
• Synonyms: 5-BROMO-2-HYDROXY-4-METHYL-3-NITROPYRIDINE;5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE;5-BROMO-4-METHYL-3-NITRO-2(1H)-PYRIDINONE;5-BROMO-4-METHYL-3-NITROPYRIDIN-2-OL;2-Hydroxy-3-Nitro-5-Bromo-4-Picoline;5-Bromo-2-hydroxy-4-methyl-3-nitropyridine 98%;5-Bromo-4-methyl-3-nitro-2-hydroxypyridine;5-BroMo-4-Methyl-3-nitropyridin-2(1H)-one
• CAS NO: 228410-90-0
• Molecular Formula: C₆H₅BrN₂O₃
• Molecular Weight: 233.02
• Product Categories: blocks;Bromides;Pyridines;Pyridine;API intermediates;Pyridine Series
• Mol File: 228410-90-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 240-243
• Boiling Point: 298.2 °C at 760 mmHg
• Flash Point: 134.1 °C
• Appearance: /
• Density: 1.84 g/cm³
• Vapor Pressure: 0.00129mmHg at 25°C
• Refractive Index: 1.62
• Storage Temp.: Keep Cold
• PKA: 6.34±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE(228410-90-0)
• EPA Substance Registry System: 5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE(228410-90-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 228410-90-0(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-hydroxy-3-nitro-4-picoline is a chemical compound that belongs to the picoline family, which consists of organic compounds. It is a derivative of pyridine and contains a nitro, hydroxy, and bromo group. 5-BROMO-2-HYDROXY-3-NITRO-4-PICOLINE is commonly used in the pharmaceutical and agrochemical industries as a building block in the synthesis of various compounds. It can also be used in the production of dyes and other organic chemicals. Furthermore, it has been studied for its potential biological and medicinal properties, including its anti-cancer and anti-inflammatory effects. Overall, 5-Bromo-2-hydroxy-3-nitro-4-picoline is a versatile compound with various industrial and potential therapeutic applications.

InChI:InChI=1/C6H5BrN2O3/c1-3-4(7)2-8-6(10)5(3)9(11)12/h2H,1H3,(H,8,10)

Upstream product

• 21901-18-8 4-Methyl-3-nitro-2-pyridone 
• 695-34-1 2-Amino-4-methylpyridine 
• 67-56-1 methanol 
• 100367-40-6 2-amino-3-nitro-4-methyl-5-bromopyridine 
• 98198-48-2 2-amino-5-bromo-4-methylpyridine 
• 142404-82-8 N-(5-bromo-4-methylpyridin-2-yl)acetamide 
• 5327-32-2 2-acetylamino-4-methylpyridine 
• 6635-86-5 2-amino-4-methyl-3-nitropyridine 
• 21901-18-8 2-hydroxy-4-methyl-3-nitropyridine 

Downstream Products

• 1430096-94-8 C₃₂H₄₁N₇O₉ 
• 1430096-96-0 C₅₄H₇₀N₈O₁₆ 
• 1445993-87-2 4-bromo-6-methyl-1-[(4-methylphenyl)sulfonyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1361481-63-1 4-bromo-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1622302-83-3 4-(tert-butyl)-N-(2-methyl-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)benzamide 
• 1622303-43-8 4-(tert-butyl)-N-(2-methyl-3-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)benzamide 
• 1622303-44-9 4-(tert-butyl)-N-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)benzamide 
• 1622303-45-0 4-(tert-butyl)-N-(2-(hydroxymethyl)-3-(6-methyl-7-oxo-1-tosyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)benzamide 
• 1445993-96-3 ethyl 4-bromo-6-methyl-7-oxo-1-toluenesulfonyl-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxylate 
• 1446237-40-6 5-bromo-1,4-dimethyl-3-nitro-1,2-dihydropyridin-2-one 

Relevant articles and documents

Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor

We previously reported the 2-oxopyridine-3-carboxamide derivative EC21a as the first small synthetic CB2R positive allosteric modulator which displayed antinociceptive activity in vivo in an experimental mouse model of neuropathic pain. Herein, we extended the structure-activity relationships of EC21a through structural modifications regarding the p-fluoro benzyl moiety at position 1 and the amide group in position 3 of the central core. The characterization in vitro was assessed through radioligand binding experiments and functional assays (GTPγS, cAMP, βarrestin2). Among the new compounds, the derivatives A1 (SV-10a) and A5 (SB-13a) characterized respectively by fluorine atom or by chlorine atom in ortho position of the benzylic group at position 1 and by a cycloheptane-carboxamide at position 3 of the central core, showed positive allosteric behavior on CB2R. They enhanced the efficacy of CP55,940 in [35S]GTPγS assay, and modulated CP55,940-dependent βarrestin2 recruitment and cAMP inhibition. The obtained results extend our knowledge of the structural requirements for interaction with the allosteric site of CB2R.

Compound with BRD4 inhibitory activity, preparation method and application thereof

The invention discloses a compound with BRD4 inhibitory activity, a preparation method and application thereof. The structure of the compound with the BRD4 inhibitory activity is shown as a formula I, and definitions of substituent groups are shown in the specification and claims. The compound provided by the invention has very high bromodomain protein inhibition activity, especially BRD4 targeted inhibition activity, and can be used for treating or/and preventing related diseases mediated by bromodomain protein.

SUBSTITUTED 1H-PYRROLOPYRIDINONE DERIVATIVES AS KINASE INHIBITORS

The present invention provides novel substituted 1H-Pyrrolopyridinone derivatives of formula (1) as protein kinase inhibitors, in which R1, R2, R3, R4, R5, R6 and 'p' have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly BTK enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.